Literature DB >> 10482382

Validation of the cerebellum as a reference region for SPECT quantification in patients suffering from dementia of the Alzheimer type.

B A Pickut1, R A Dierckx, A Dobbeleir, K Audenaert, K Van Laere, A Vervaet, P P De Deyn.   

Abstract

In longitudinal brain studies of dementia of the Alzheimer type (DAT), the cerebellum is often used as a reference region for single photon emission computed tomography (SPECT) quantification, which assumes no significant regional influence of physiological fluctuations or pathology. With the use of absolute quantification in DAT patients, reproducibility of cerebellar uptake of technetium-99m-d,l-hexamethylpropyleneamine oxime (HMPAO) was tested and compared with the mean absolute cerebellar tracer uptake value in DAT patients and healthy control subjects. In 13 DAT patients SPECT studies were repeated within 2 weeks to assess reproducibility of cerebellar regional brain uptake (rBU). With calibrated point sources as scaling factors, cerebellar activity was expressed as rBU of HMPAO per cm3 brain tissue in percent of the injected lipophilic dose of 740 MBq (20 mCi). Also, mean cerebellar rBU in patients suffering from DAT was calculated and compared with a previously established database obtained in healthy volunteers. Repeated SPECT studies within a 2-week interval in clinically stable patients resulted in a mean rBU increase of 6.8 +/- 10.3% in the second SPECT study as compared with the first. A similar shift was previously reported in healthy volunteers. Mean cortical cerebellar rBU values in DAT patients and in the healthy reference population concurred, after cumulative corrections for body surface and for a mean brain volume of 1350 ml (obtained in healthy control subjects), showing respective mean values of 53.9 +/- 7.4 and of 52.0 +/- 7.3 x 10(-6) of the injected lipophilic dose 740 MBq (20 mCi) of HMPAO per cm3 of brain tissue. A unidirectional shift in mean absolute cerebellar uptake values occurs between repeat SPECT examinations in DAT patients similar to previous findings in a group of healthy volunteers. The origin of this phenomenon remains elusive but deserves further study with regard to SPECT (semi)quantification in DAT patients. Most interestingly, the presented findings suggest that with the use of HMPAO SPECT in DAT patients the cerebellum remains scintigraphically uninvolved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482382     DOI: 10.1016/s0925-4927(99)00004-9

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  13 in total

1.  Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow.

Authors:  Bich-Ngoc-Thanh Tang; Satoshi Minoshima; Jean George; Annie Robert; Christian Swine; Patrice Laloux; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

2.  Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load.

Authors:  A Bozzao; R Floris; M E Baviera; A Apruzzese; G Simonetti
Journal:  AJNR Am J Neuroradiol       Date:  2001 Jun-Jul       Impact factor: 3.825

3.  Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer's disease.

Authors:  Elena Rodriguez-Vieitez; Antoine Leuzy; Konstantinos Chiotis; Laure Saint-Aubert; Anders Wall; Agneta Nordberg
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

4.  Regional Cerebral Blood Flow Correlates of Neuropsychiatric Symptom Domains in Early Alzheimer's Disease.

Authors:  Hyeonseok Jeong; Ilhyang Kang; Jong-Sik Park; Seung-Hee Na; Seunghee Kim; Sujung Yoon; In-Uk Song; Yong-An Chung
Journal:  Diagnostics (Basel)       Date:  2022-05-17

5.  alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis.

Authors:  Emma Terrière; Mike Sharman; Claire Donaghey; Lucie Herrmann; Jane Lonie; Marion Strachan; Nadine Dougall; Jonathan Best; Klaus P Ebmeier; Sally Pimlott; Jim Patterson; David Wyper
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

6.  Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease.

Authors:  Naama Levy-Cooperman; Amer M Burhan; Shahryar Rafi-Tari; Maggie Kusano; Joel Ramirez; Curtis Caldwell; Sandra E Black
Journal:  J Psychiatry Neurosci       Date:  2008-05       Impact factor: 6.186

7.  Divergent regional patterns of cerebral hypoperfusion and gray matter atrophy in mild cognitive impairment patients.

Authors:  Miranka Wirth; Alexa Pichet Binette; Peter Brunecker; Theresa Köbe; A Veronica Witte; Agnes Flöel
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

8.  Cerebral Perfusion Insufficiency and Relationships with Cognitive Deficits in Alzheimer's Disease: A Multiparametric Neuroimaging Study.

Authors:  Chi-Wei Huang; Shih-Wei Hsu; Ya-Ting Chang; Shu-Hua Huang; Yung-Cheng Huang; Chen-Chang Lee; Wen-Neng Chang; Chun-Chung Lui; Na-Ching Chen; Chiung-Chih Chang
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

9.  Cerebral Perfusion Changes after Acetyl-L-Carnitine Treatment in Early Alzheimer's Disease Using Single Photon Emission Computed Tomography.

Authors:  Hyeonseok S Jeong; Jong-Sik Park; YoungSoon Yang; Seung-Hee Na; Yong-An Chung; In-Uk Song
Journal:  Dement Neurocogn Disord       Date:  2017-03-31

10.  Unidirectional Influx and Net Accumulation of PIB.

Authors:  Gunnar Blomquist; Henry Engler; Agneta Nordberg; Anna Ringheim; Anders Wall; Anton Forsberg; Sergio Estrada; Pernilla Frändberg; Gunnar Antoni; Bengt Långström
Journal:  Open Neuroimag J       Date:  2008-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.